Plain-English translation of NCT07015242 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The CAROLYN trial is testing a new cell therapy called lisocabtagene maraleucel (also called or Breyanzi) to see if it works well as a first treatment for a specific type of brain lymphoma in patients who cannot have a stem cell transplant. This medication works by using your own immune cells, training them to recognize and fight cancer cells, and then putting them back into your body. The trial will look at how safe the treatment is and how many patients respond well to it.
Patients with this type of brain lymphoma who cannot have a stem cell transplant need new treatment options. This trial exists to see if this new cell therapy can help these patients more effectively than standard treatments alone.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the new cell therapy treatment as an outpatient or inpatient, depending on what your medical team decides is best. The treatment involves collecting some of your own immune cells, processing them in a laboratory to train them to fight cancer, and then infusing them back into your body. You will have regular doctor visits and tests (blood work, imaging scans) to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States